statement
IMVT-1402 is designed so its binding epitope does not compete with albumin, allowing high-dose continuous administration without hypercholesterolemia concerns, whereas Batoclimab requires dose reduction after several weeks.
A statement by 하나증권 제약/바이오 김선아. Statements are as reported by the cited publishers — not verified by DecisionGateway.
IMVT-1402는 결합 위치(epitope)가 알부민과 경쟁하지 않도록 설계되어 고콜레스테롤혈증 우려 없이 고용량 지속 투여 가능 (Batoclimab은 수 주 투약 후 감량 필요)
Discussion
Related claims
IMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statementThis is the first case clinically demonstrating the strategic advantage IMVT-1402 has over Batoclimab.하나증권 제약/바이오 김선아 · statementImmunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statementFollowing the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementIMVT-1402 value was calculated at approximately 3.7 trillion won.하나증권 제약/바이오 김선아 · statementIn the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statement